Pharmaceutical Executive April 2, 2024
Mills is working in leadership in two roles, one of which puts her on the forefront of the genomic medicine movement.
Demaris Mills is serving as both president of Integrated DNA Technologies and vice president and group executive of genomic medicines at Danaher. She recently spoke with Pharmaceutical Executive about the state of genomic medicine and how she’s balancing both roles at the same time.
Pharmaceutical Executive: What is the current state of genomic medicines?
Demaris Mills: We have unlocked an exciting chapter in genomic medicine—one that has transformed healthcare as we know it—with the FDA’s landmark approval of the first commercially available CRISPR-based gene therapy for the treatment of sickle cell disease late last year. With more promising treatments in...
Today's Sponsors
Today's Sponsor